Legal Lingo: Real estate funds 101
Being an aspiring commercial lawyer often means being confronted by complex, often abstract, concepts leading to an often impenetrable...
Contributors
-
Associate -
Trainee -
Partner -
Trainee -
Counsel -
Partner -
Trainee -
Partner -
Counsel -
Associate
-
Partner -
Partner -
Partner -
Partner -
Associate
-
Director of Human Resources, London
-
Partner -
Senior Lab Consultant and Behavioral Scientist -
Associate -
Antitrust Professional Support Lawyer
-
Partner -
Counsel -
Associate
-
Associate -
Counsel -
Partner -
Counsel -
Partner -
Associate -
Associate -
Trainee -
Partner -
Associate -
Partner -
Associate -
Partner -
International Pro Bono -
Associate -
Associate -
Associate -
Partner -
Partner -
Trainee -
Associate
-
Partner -
Partner -
Associate -
Senior Manager, Professional Development and Training -
Associate -
Trainee -
Chief of Change and Engagement -
Trainee -
Associate -
Counsel -
Associate -
Partner -
Counsel -
Associate -
Trainee
-
Associate -
Partner -
Trainee -
Associate -
Associate -
Trainee Solicitor -
Associate -
Director of Behavioral Insights -
Associate -
Counsel -
Associate -
Associate -
Partner -
Associate -
Partner -
Associate -
Partner -
Associate -
Associate -
Counsel -
Partner -
Partner -
Associate -
Partner -
Associate -
Associate -
Partner -
Associate
-
Partner -
Associate -
Partner -
Associate -
Partner -
Trainee -
Trainee -
Managing Principal and Head of Innovation of R&G Insights Lab -
Associate
Ropes & Gray Archive
- February 2023 (1)
- January 2023 (27)
- December 2022 (11)
- November 2022 (22)
- October 2022 (12)
- September 2022 (9)
- August 2022 (5)
- July 2022 (7)
- June 2022 (8)
- May 2022 (10)
- April 2022 (7)
- March 2022 (18)
- February 2022 (6)
- January 2022 (12)
- December 2021 (10)
- November 2021 (16)
- October 2021 (7)
- September 2021 (10)
- August 2021 (12)
- July 2021 (22)
- June 2021 (17)
- May 2021 (10)
- April 2021 (9)
- March 2021 (7)
- February 2021 (13)
- January 2021 (19)
- December 2020 (14)
- November 2020 (11)
- October 2020 (16)
- September 2020 (12)
- August 2020 (13)
- July 2020 (32)
- June 2020 (19)
- May 2020 (33)
- April 2020 (38)
- March 2020 (53)
- February 2020 (22)
Making the transition from medical devices to medtech
Our handling of, and emergence from, the COVID-19 pandemic has, in no small part, been due to the many significant advances made by big...
UK poised to finalise “failure to prevent fraud” offence
The United Kingdom has pioneered corporate “failure to prevent” offences in the context of the UK Bribery Act 2010 (UKBA) and the...
UK consultation on R&D tax relief raises questions for life sciences
As we have discussed in recent posts, the UK Government has set its hopes for growth on becoming a ‘science superpower’. A key part of...
Life sciences - key developments to expect in 2023 and beyond
A recently published alert, which can be found here, provides a reflection of the challenges and the growth-driving opportunities...
What drives a successful GP-LP relationship?
I recently sat down with my asset management colleagues, Emily Brown in London, and Vince Ip and Chune Loong Lum in Hong Kong, to...
Cybersecurity - private equity firms sharpen their focus
Cybersecurity has become an increasingly regulated area of risk for many businesses in the digital world. As technology has advanced and...
Metamorphosis of contractual necessity as a lawful basis of processing under the GDPR
Under the GDPR, the processing of personal data requires a lawful basis. These include, among others, the processing of data: with the...
European restructuring & insolvency – what we saw in 2022 and what to expect in 2023
As 2023 gets underway, we've taken the opportunity here to look at what we saw in the European distressed market in 2022, as well as...
Private funds – what we expect to see in 2023
As we start the New Year, we look ahead at trends we expect to see in the private fundraising space.
According to data from Preqin in...
Private equity investment: Trends to expect in 2023
In contrast to the remarkable levels of deal activity seen in 2021, the last 12 months have been more challenging for private equity...
Tick, tock: countdown begins to EU cyber laws
Two years can feel like a long time, but it’s really not. The Beatles released Help!, Rubber Soul, Revolver and Sgt. Pepper’s...
A guide on key legal issues facing PE deal makers in the UK
The UK Chapter of The Legal 500: Private Equity Comparative Guide 2023 – authored by private equity transaction partners John Newton and...
Legal Lingo: What is a syndicated loan?
Being an aspiring commercial lawyer often means being confronted by complex, often abstract, concepts leading to an often impenetrable...
A year of the NSIA – The good, the bad and the ugly
The UK's National Security and Investment Act 2021 (NSIA) – the UK equivalent of CFIUS – entered into force on January 4, 2022 and...
Reflections for dealmakers from JPMorgan Healthcare Conference 2023
As everyone unpacks from last week's JPMorgan Healthcare Conference 2023 and digests their various meetings, it is worth reflecting on...
GP-led secondaries: What they are, how they work and why they’re not going away
I had the privilege of participating in an engaging Practising Law Institute (PLI) panel discussion yesterday on 'GP-Led Secondaries:...
Lithuanian railways judgment arrives in great haste
This week, the European Court of Justice (CJEU) upheld the General Court’s judgment and European Commission’s decision to fine the...
Royal Mail suffers disruption following "cyber incident"
Following a number of recent cyber-security related events in the UK (for example, the suspected ransomware attack on The Guardian...
DPA corrective measures: It’s not all about the fine
Last November I moderated a panel at the Privacy + Security Academy Forum on the implications of non-financial sanctions being issued by...
Will 2023 be the year that the UK finally becomes a ‘science superpower’?
We have previously noted that 2023 may be a blockbuster year for European biotech deal making. A recent article in the Financial Times
Considerations for institutional investors contemplating a secondary sale
With 2023 upon us, here are a few considerations for institutional investors contemplating a secondary sale, including:
- Why an investor...
EC proposal to amend the transitional provisions for medical devices and in vitro diagnostic medical devices
On 6 January 2023, the European Commission (EC) published the legislative proposal to extend or amend the transitional deadlines for...
UK Purpose Built Student Accommodation – a safe port in a stormy 2023?
With a chronic undersupply of beds struggling to keep pace with booming student demand, Purpose Built Student Accommodation (PBSA) could...
GDPR and clinical research: time for a rethink?
Although it’s become an increasingly common occurrence, I can’t help but feeling excited whenever the Financial Times reports on data...
Are compliance teams prepared for 2023?
The combination of continuing challenges arising from COVID and potential future economic headwinds could create a perfect storm for...
What to expect from the European life sciences and healthcare market in 2023
As we start 2023, we look ahead to the trends that we can expect from the European life sciences and healthcare market. The conditions...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net